Evaluation of bleeding risk in patients with acute coronary syndrome treated with tirofiban after different percutaneous coronary interventions

Abstract

Objective To explore the bleeding risk in patients with acute coronary syndrome(ACS)treated with tirofiban after percutaneous coronary intervention(PCI)with different approaches. Methods Retrospective analysis of 403 patients with ACS in our hospital was performed.According to whether tirofiban was used, those patients were divided into the tirofiban group and the non-tirofiban group.The rate of bleeding events after PCI was assessed in both groups. Results For the radial artery approach, there was no significant difference on the rate of non-severe bleeding events between tirofiban group and the non-tirofiban group(6.87% vs.5.10%, χ2=0.075, P=0.784). For femoral artery approach, the rate of non-severe bleeding events was significantly higher in tirofiban group than in non-tirofiban group(23.15% vs. 9.09%, χ2=4.610, P=0.031). For the radial artery approach, there was no significant difference on the rate of bleeding of puncture site between tirofiban group and non-tirofiban group(1.53% vs. 1.02%, χ2=0.064, P=0.799). For the femoral artery approach, the rate of bleeding of puncture site was significantly higher in tirofiban group than in non-tirofiban group(15.74% vs. 4.55%, χ2=4.006, P=0.045). The rate of non-severe bleeding events and bleeding of puncture site of tirofiban was significantly higher in the femoral artery approach than radical artery approach(χ2=11.555, P=0.0006 and χ2=14.459, P=0.0001 respectively). Conclusions Compared with the femoral artery approach, the rate of bleeding events of tirofiban in patients with ACS treated by PCI is lower in the radial artery approach.It is recommended to be used individually based on guidelines. Key words: Tirofiban; Angioplasty, transluminal, percutaneous coronary; Acute coronary syndrome; Bleeding events